Amylyx Drug Shows Promise for Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals has reported promising results from a late-stage trial for avexitide, an experimental treatment for post-bariatric hypoglycemia. This condition, characterized by dangerously low blood sugar levels after weight-loss surgery, affects approximately 8% of such patients in the United States and currently has no approved therapies.

The 78-patient study demonstrated that avexitide, administered as a once-daily injection, successfully reduced episodes of low blood sugar by 55% compared to a placebo over a 16-week period. The drug's mechanism involves blocking GLP-1 receptors in the pancreas to regulate insulin secretion and stabilize glucose levels.

Patients typically manage the condition through dietary adjustments and medications. Avexitide was found to be well-tolerated, with common side effects being mild. Amylyx acquired the drug from Eiger BioPharmaceuticals and plans to submit it for U.S. regulatory approval by the end of this year, with a potential commercial launch anticipated in 2027.

Analysts project significant sales potential for avexitide, highlighting the unmet need for effective treatments. The drug's safety profile was favorable, with no observed impact on body weight during the trial. Regulatory submission is a key step toward addressing this significant post-surgical complication.